c2.KEGG MEDICUS PATHOGEN HTLV 1 P12 TO ANTIGEN PROCESSING AND PRESENTATION BY MHC CLASS I MOLECULE c2.KEGG MEDICUS REFERENCE TRANSLATION INITIATIO c2.KEGG MEDICUS REFERENCE UCHL1 MEDIATED HYDROLYS c2.REACTOME SARS COV 1 MODULATES HOST TRANSLATION MACHINER c2.KEGG RIBOSOM c2.REACTOME EUKARYOTIC TRANSLATION ELONGATIO c2.KEGG MEDICUS REFERENCE ANXA2 S100A10 REGULATED ACTIN CYTOSKELETO c2.REACTOME ENDOSOMAL VACUOLAR PATHW c2.REACTOME ACTIVATION OF THE MRNA UPON BINDING OF THE CAP BINDING COMPLEX AND EIFS AND SUBSEQUENT BINDING TO 4: c2.REACTOME SRP DEPENDENT COTRANSLATIONAL PROTEIN TARGETING TO MEMBRAN	ES DN SIS RY ME DN DN DN AY DH SIS NE	ndle and epithelioid tun	Gliomas	Glioneuronal tumors	
c2.WP CYTOPLASMIC RIBOSOMAL PROTEIN c2.REACTOME FOLDING OF ACTIN BY CCT TR c2.LUI THYROID CANCER CLUSTER c2.KEGG MEDICUS PATHOGEN ESCHERICHIA ESPT TO RAC SIGNALING PATHW. c2.BIOCARTA IRES PATHW. c2.REACTOME EUKARYOTIC TRANSLATION INITIATIC c2.KEGG MEDICUS PATHOGEN SHIGELLA IPAC TO ACTIN SIGNALING PATHW. c2.MIKHAYLOVA OXIDATIVE STRESS RESPONSE VIA VHL U c2.KEGG MEDICUS PATHOGEN ESCHERICHIA MAP TO CDC42 SIGNALING PATHW. c2.BILANGES SERUM AND RAPAMYCIN SENSITIVE GENE c2.REACTOME RESPONSE OF EIF2AK4 GCN2 TO AMINO ACID DEFICIENC c2.LUI TARGETS OF PAX8 PPARG FUSIC c2.REACTOME UPTAKE AND FUNCTION OF DIPHTHERIA TOX c2.WP GLIAL CELL DIFFERENTIATIC c2.WP NSP1 FROM SARSCOV2 INHIBITS TRANSLATION INITIATION IN THE HOST CE c2.REACTOME FORMATION OF TUBULIN FOLDING INTERMEDIATES BY CCT TR c2.CHNG MULTIPLE MYELOMA HYPERPLOID U c2.KEGG MEDICUS PATHOGEN HCV CORE TO ERK SIGNALING PATHW. c2.REACTOME NONSENSE MEDIATED DECAY NIM c2.REACTOME NONSENSE MEDIATED DECAY NIM c2.REACTOME SCREWERS SERVEN AND	RIC R 3 AY AY AY ON AY ON AY ON ON CIT				
c2.BILANGES SERUM RESPONSE TRANSLATIC c2.KEGG MEDICUS PATHOGEN SARS COV 2 S TO CLASSICAL PATHWAY OF COMPLEMENT CASCAI c2.BIOCARTA CDC42RAC PATHWAY c2.TIEN INTESTINE PROBIOTICS 6HR I c2.REACTOME GAP JUNCTION DEGRADATIC c2.WATERMAN IPF VS CTRL CD8T I c2.KEGG MEDICUS PATHOGEN SALMONELLA SOPE TO RAC SIGNALING PATHWA c2.KEGG MEDICUS PATHOGEN ESCHERICHIA ESPG TO MICROTUBULE RHOA SIGNALING PATHWA c2.KEGG MEDICUS PATHOGEN ESCHERICHIA MAP TO LPA GNA12 13 RHOA SIGNALING PATHWA c2.KEGG MEDICUS PATHOGEN ESCHERICHIA MAP TO LPA GNA12 13 RHOA SIGNALING PATHWA c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT DCTN1 TO RETROGRADE AXONAL TRANSPOF c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO ELECTRON TRANSFER IN COMPLEX c2.MIKHAYLOVA OXIDATIVE STRESS RESPONSE VIA VHL E c2.HISIAO HOUSEKEEPING GENE c2.REACTOME REGULATION OF PTEN LOCALIZATIC c2.KEGG MEDICUS REFERENCE AUTOPHAGOSOME AND LYSOSOME FUSION TETHERING FACTOR GRASP c2.REACTOME SPRY REGULATION OF FGF SIGNALIN c2.JIANG AGING CEREBRAL CORTEX I c2.KEGG MEDICUS ENV FACTOR ZN TO ANTEROGRADE AXONAL TRANSPOF	DE AY UP DON UP AY AY AY AY AY AY AY BON DON BES DON BON BON BON BON BON BON BON BON BON B				
C2.LAU APOPTOSIS CDKN2A I C2.REACTOME DOWNREGULATION OF ERBB4 SIGNALIN C2.KEGG MEDICUS REFERENCE AUTOPHAGY VESICLE NUCLEATION ELONGATION MATURATION SEQUESTOSOME 1 LIKE RECEPTO C2.REACTOME RESPIRATORY SYNCYTIAL VIRUS RSV GENOME REPLICATION TRANSCRIPTION AND TRANSCLAITIO C2.HEBERT MATRISOME TNBC BONE BRAIN LUNG LIVER METASTASTASES TUMOR CELL DERIVE C2.REACTOME COOPERATION OF PREFOLDIN AND TRIC CCT IN ACTIN AND TUBULIN FOLDIN C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED VCP TO 26S PROTEASOME MEDIATED PROTEIN DEGRADATIO C2.WP GLYCOLYSIS IN SENESCENC C2.WP GLYCOLYSIS IN SENESCENC C2.KEGG MEDICUS PATHOGEN ESCHERICHIA EAE TIR TCCP TO ACTIN SIGNALING PATHW. C2.KEGG MEDICUS VARIANT MUTATION ACTIVATED BRAF TO ERK SIGNALING PATHW. C2.KEGG MEDICUS REFERENCE 26S PROTEASOME MEDIATED PROTEIN DEGRADATIO C2.KEGG MEDICUS VARIANT SOD1 TO 26S PROTEASOME MEDIATED PROTEIN DEGRADATIO C2.REACTOME NEF MEDIATED CD8 DOWN REGULATIO C2.REACTOME NEF MEDIATED CD8 DOWN REGULATIO C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED UBQLN2 TO 26S PROTEASOME MEDIATED PROTEIN DEGRADATIO C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED UBQLN2 TO 26S PROTEASOME MEDIATED PROTEIN DEGRADATIO C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED UBQLN2 TO 26S PROTEASOME MEDIATED PROTEIN DEGRADATIO C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED UBQLN2 TO 26S PROTEASOME MEDIATED PROTEIN DEGRADATIO C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED UBQLN2 TO 26S PROTEASOME MEDIATED PROTEIN DEGRADATIO C2.JIANG AGING HYPOTHALAMUS I C2.KEGG MEDICUS PATHOGEN SHIGELLA IPAB C D TO ITGA B TALIN VINCULIN SIGNALING PATHW.	DN NG DN				
C2.REACTOME PTK6 REGULATES RTKS AND THEIR EFFECTORS AKT1 AND DOI C2.REACTOME RHOBTB2 GTPASE CYCI C2.REACTOME SELENOAMINO ACID METABOLIS C2.REACTOME SELENOAMINO ACID METABOLIS C2.REACTOME SARS COV 2 TARGETS HOST INTRACELLULAR SIGNALLING AND REGULATORY PATHWAY C2.TIEN INTESTINE PROBIOTICS 2HR L C2.MOOTHA TO C2.VISALA RESPONSE TO HEAT SHOCK AND AGING E C2.KEGG MEDICUS VARIANT SCRAPIE CONFORMATION PRPSC TO 26S PROTEASOME MEDIATED PROTEIN DEGRADATIO C2.REACTOME REGULATION OF MITF M DEPENDENT GENES INVOLVED IN LYSOSOME BIOGENESIS AND AUTOPHAC C2.HOLLEMAN ASPARAGINASE RESISTANCE B ALL L C2.CASTELLANO HRAS TARGETS L C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO 26S PROTEASOME MEDIATED PROTEIN DEGRADATIO C2.WP CREATINE PATHW. C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO VGCC CA2 APOPTOTIC PATHWAY NO10 C2.WP TCA CYCLE NUTRIENT USE AND INVASIVENESS OF OVARIAN CANCE C2.BIOCARTA PROTEASOME PATHW. C2.HOLLEMAN VINCRISTINE RESISTANCE ALL E C2.BIOCARTA KREB PATHW.	K1 LE SSM YS UP CA DN ON ON ON ON ON ON ON ON ON ON ON ON ON				
C2.FU INTERACT WITH ALKBI C2.CDEN INTERACT WITH LCX C2.KEGG MEDICUS REFERENCE ARNO ARF ACTB G SIGNALING PATHWX C2.KEGG MEDICUS REFERENCE RAC CDC42 PAK ERK SIGNALING PATHWX C2.KEGG MEDICUS ENV FACTOR IRON TO ANTEROGRADE AXONAL TRANSPOR C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO 26S PROTEASOME MEDIATED PROTEIN DEGRADATIC C2.REACTOME FLT3 SIGNALING BY CBL MUTANT C2.KEGG MEDICUS REFERENCE CITRATE CYCLE SECOND CARBON OXIDATION C2.KEGG MEDICUS REFERENCE ELECTRON TRANSFER IN COMPLEX C2.REACTOME REGULATION OF EXPRESSION OF SLITS AND ROBC C2.LUI THYROID CANCER PAX8 PPARG E C2.MOOTHA RC C2.REACTOME FIBRONECTIN MATRIX FORMATIC C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT SNCA TO 26S PROTEASOME MEDIATED PROTEIN DEGRADATIC C2.KEGG MEDICUS REFERENCE PROMOTION OF MICROTUBULE GROWT C2.REACTOME NEGATIVE FEEDBACK REGULATION OF MAPK PATHWX C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO ELECTRON TRANSFER IN COMPLEX C2.WP TCA CYCLE AKA KREBS OR CITRIC ACID CYCLE	H8 A5 AY AY RT DN TS N 2 IIII DS DN DN TH AY AY LIIII LE				
C2.BIOCARTA MALATEX PATHW. C2.BIOCARTA SUMO PATHW. C2.BIOCARTA SUMO PATHW. C2.BIOCARTA HSWI SNF PATHW. C2.CALVET IRINOTECAN SENSITIVE VS REVERTED I C2.REACTOME PTK6 REGULATES RHO GTPASES RAS GTPASE AND MAP KINASI C2.REACTOME SIGNALING BY MRAS COMPLEX MUTANT C2.REACTOME TRANSPORT OF CONNEXONS TO THE PLASMA MEMBRAN C2.REACTOME SUMO IS CONJUGATED TO E1 UBA2 SAI C2.BIOCARTA ETC PATHW. C2.DISTECHE ESCAPED FROM X INACTIVATIC C2.KEGG MEDICUS REFERENCE COPI VESICLE FORMATIC C2.KEGG MEDICUS REFERENCE COPI VESICLE FORMATIC C2.REACTOME SARS COV 2 MODULATES HOST TRANSLATION MACHINEF C2.KEGG MEDICUS PATHOGEN ESCHERICHIA EAE TIR TO ACTIN SIGNALING PATHW. C2.KEGG MEDICUS REFERENCE KINETOCHORE FIBER ORGANIZATIC C2.REACTOME RHO GTPASES ACTIVATE (QGAF C2.KEGG MEDICUS VARIANT MUTATION ACTIVATED KRAS NRAS TO ERK SIGNALING PATHW. C2.KEGG MEDICUS VARIANT MUTATION ACTIVATED KRAS NRAS TO ERK SIGNALING PATHW. C2.WHITESIDE CISPLATIN RESISTANCE I	AY AY AY UP ES TS NE E1 AY ON ON ON ON EN				
C2.CAFFAREL RESPONSE TO THC 24HR 3 L C2.REACTOME SARS COV 1 TARGETS HOST INTRACELLULAR SIGNALLING AND REGULATORY PATHWAY C2.COLIN PILOCYTIC ASTROCYTOMA VS GLIOBLASTOMA L C2.JANG AGING HYPOTHALAMUS L C2.FLOTHO PEDIATRIC ALL THERAPY RESPONSE L C2.REACTOME MODULATION BY MTB OF HOST IMMUNE SYSTE C2.LI WILMS TUMOR ANAPLASTIC E C2.REACTOME GENE AND PROTEIN EXPRESSION BY JAK STAT SIGNALING AFTER INTERLEUKIN 12 STIMULATIC C2.KEGG PROTEASON C2.WP PROTEASOME DEGRADATIC C2.NABA MATRISOME MULTIPLE MYELOM C2.MODY HIPPOCAMPUS NEONAT C2.REACTOME NEGATIVE REGULATION OF NOTCH4 SIGNALIN C2.REACTOME FBXW7 MUTANTS AND NOTCH1 IN CANCE C2.REACTOME ADVANCED GLYCOSYLATION ENDPRODUCT RECEPTOR SIGNALIN C2.KEGG MEDICUS REFERENCE KINETOCHORE MICROTUBULE ATTACHMEN C2.REACTOME INFLUENZA INFECTIO	UP UP UP UP UP ON ON ME ON MA AL ED NG ER NG NT ON NT ON				
C2.KEGG MEDICUS ENV FACTOR METALS TO RAS ERK SIGNALING PATHW, C2.RAMPON ENRICHED LEARNING ENVIRONMENT EARLY U C2.REACTOME CONSTITUTIVE SIGNALING BY LIGAND RESPONSIVE EGFR CANCER VARIANT C2.LIU CMYB TARGETS I C2.WP PILOCYTIC ASTROCYTOM C2.REACTOME IFNG SIGNALING ACTIVATES MAPH C2.BIOCARTA MTOR PATHW. C2.GUTIERREZ MULTIPLE MYELOMA U C2.BIOCARTA PTEN PATHW. C2.GUTIERREZ MULTIPLE MYELOMA U C2.BIOCARTA PTEN PATHW. C2.MYLLYKANGAS AMPLIFICATION HOT SPOT C2.KEGG MEDICUS REFERENCE REGULATION OF GF RTK RAS ERK SIGNALING SPRED AND N C2.SCHAEFFER PROSTATE DEVELOPMENT AND CANCER BOX2 U C2.KEGG MEDICUS PATHOGEN SHIGELLA OSPG TO TNF NFKB SIGNALING PATHW. C2.KEGG MEDICUS REFERENCE CLASSICAL PATHWAY OF COMPLEMENT CASCADE C4 C2 TO C3 CONVERTASE FORMATIC C2.KEGG MEDICUS VARIANT AMPLIFIED PDGFR TO RAS ERK SIGNALING PATHW. C2.MARIADASON RESPONSE TO BUTYRATE CURCUMIN SULINDAC TSA C2.REACTOME Z DECAY DEGRADATION OF MATERNAL MRNAS BY ZYGOTICALLY EXPRESSED FACTOF C2.REACTOME Z DECAY DEGRADATION OF MATERNAL MRNAS BY ZYGOTICALLY EXPRESSED FACTOF	UP TS DN MA KS AY UP AY F1 UP ON AY				
C2.REACTOME CELLULAR RESPONSE TO STARVATION C2.KEGG MEDICUS PATHOGEN HCMV GB TO PDGFR RAS ERK SIGNALING PATHW. C2.KEGG MEDICUS PATHOGEN HCMV GB TO PDGFR RAS ERK SIGNALING PATHW. C2.REACTOME RHOBTB GTPASE CYCLOW. C2.MALONEY RESPONSE TO 17AAG I C2.BIOCARTA PYK2 PATHW. C2.BIOCARTA PYK2 PATHW. C2.REACTOME PEXOPHAC C2.REACTOME PEXOPHAC C2.REACTOME AUF1 HNRNP D0 BINDS AND DESTABILIZES MRN C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT TDP43 TO ELECTRON TRANSFER IN COMPLE: C2.REACTOME COHESIN LOADING ONTO CHROMAT C2.JOHANSSON BRAIN CANCER EARLY VS LATE C2.CHESLER BRAIN HIGHEST EXPRESSION C2.REACTOME COPI INDEPENDENT GOLGI TO ER RETROGRADE TRAFF C2.WP AEROBIC GLYCOLYS C2.PID S1P S1P4 PATHW. C2.KEGG MEDICUS VARIANT SCRAPIE CONFORMATION PRPSC TO PERK ATF4 SIGNALING PATHW. C2.YANAGISAWA LUNG CANCER RECURRENCE C2.GNATENKO PLATELET SIGNATURE.	AY LE DON AY GY X I NA X I IN DON DON DON DON DON CON ESSIS AY AY AY AY AY AY AY AY AFRE				
C2.KEGG MEDICUS REFERENCE ELECTRON TRANSFER IN COMPLEY C2.HONMA DOCETAXEL RESISTANG C2.CHAUHAN RESPONSE TO METHOXYESTRADIOLE C2.IIZUKA LIVER CANCER PROGRESSION LO L1 I C2.REACTOME PREVENTION OF PHAGOSOMAL LYSOSOMAL FUSIC C2.BIOCARTA EIF4 PATHW. C2.KEGG MEDICUS PATHOGEN SHIGELLA IPGD TO ARNO AFF ACTB G SIGNALING PATHW. C2.KEGG MEDICUS PATHOGEN SHIGELLA IPGD TO ARNO AFF ACTB G SIGNALING PATHW. C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED PROKE TO PROKE PRICE OF RESPONSE TO AMPROSTINE IN C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED PROKES TO PROKES TO AMPROSTINE IN C2.MANN RESPONSE TO AMPROSTINE IN C2.REACTOME RHO GTPASES ACTIVATE ROCE OF A C2.REACTOME RHO GTPASES ACTIVATE ROCE OF A C2.REACTOME REGULATION OF RUNX3 EXPRESSION AND ACTIVITY OF A C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT SNCA TO ELECTRON TRANSFER IN COMPLES OF A C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED FGF17 TO RAS ERK SIGNALING PATHW. C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED FGF17 TO RAS ERK SIGNALING PATHW. C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED FGF17 TO RAS ERK SIGNALING PATHW. C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED FGF17 TO RAS ERK SIGNALING PATHW. C2.CAZARD UV RESPONSE CLUSTER (C2.REACTOME SIGNALING BY PDGFRA TRANSMEMBRANE JUXTAMEMBRANE AND KINASE DOMAIN MUTAN)	CE DN DN DN DN AY AY AY AY DN TY X I DN TY X I DN AY				
c2.REACTOME INLA MEDIATED ENTRY OF LISTERIA MONOCYTOGENES INTO HOST CELI c2.TAKAO RESPONSE TO UVB RADIATION I c2.KEGG MEDICUS PATHOGEN HPV E5 TO EGFR RAS ERK SIGNALING PATHW, c2.CHANDRAN METASTASIS TOP50 L c2.BIOCARTA ECM PATHW, c2.REACTOME DEGRADATION OF GLI1 BY THE PROTEASOM c2.KEGG MEDICUS REFERENCE ANTEROGRADE AXONAL TRANSPOR c2.HE PTEN TARGETS D c2.CHOI ATL CHRONIC VS ACUTE D c2.REACTOME SIGNALING BY FGFR4 IN DISEAS c2.REACTOME DEGRADATION OF AX c2.KEGG MEDICUS REFERENCE CITRATE CYCLE FIRST CARBON OXIDATIO c2.KEGG MEDICUS REFERENCE CXCR4 GNA12 13 RHO SIGNALING PATHW, c2.KEGG MEDICUS REFERENCE CXCR4 GNA12 13 RHO SIGNALING PATHW, c2.KEGG MEDICUS VARIANT BCR ABL FUSION KINASE TO RAS ERK SIGNALING PATHW, c2.KEGG MEDICUS REFERENCE EGF EGFR ACTIN SIGNALING PATHW,	LS UP AY UP AY AY ON DN DN DN SE SI DN DN DN ST C3 AY AY				
C2.BANDRES RESPONSE TO CARMUSTIN WITHOUT MGMT 24HR E C2.KEGG MEDICUS REFERENCE MICROTUBULE DEPOLYMERIZATION AT THE MINUS END C2.MACLACHLAN BRCA1 TARGETS L C2.HOLLEMAN VINCRISTINE RESISTANCE B ALL E C2.HOLLEMAN VINCRISTINE RESISTANCE B ALL E C2.REACTOME STABILIZATION OF P C2.ALONSO METASTASIS NEURAL L C2.REACTOME CONSTITUTIVE SIGNALING BY OVEREXPRESSED ERBI C2.REACTOME THE ROLE OF GTSE1 IN G2 M PROGRESSION AFTER G2 CHECKPOIR C2.KEGG MEDICUS PATHOGEN SALMONELLA SIFA TO MICROTUBULE PLUS END DIRECTED TRANSPOR C2.REACTOME INSULIN RECEPTOR RECYCLIN C2.REACTOME RECYCLING PATHWAY OF C2.REACTOME SIGNALING BY CTNNB1 PHOSPHO SITE MUTANT C2.KEGG MEDICUS PATHOGEN HBV HBX TO RAS ERK SIGNALING PATHWA C2.KEGG MEDICUS VARIANT AMPLIFIED MYCN TO TRANSCRIPTIONAL ACTIVATIVE C2.KEGG MEDICUS VARIANT AMPLIFIED MYCN TO TRANSCRIPTIONAL ACTIVATIVE C2.NADLER OBESITY L C2.REACTOME SCF BETA TRCP MEDIATED DEGRADATION OF EM C2.BIOCARTA ERAD PATHWA C3.BIOCARTA ERAD PATHWA C4.BIOCARTA	DN DS DS DDN DS DDN DS DDN DS DDN DDN DD				
C2.WP TCA CYCLE AND DEFICIENCY OF PYRUVATE DEHYDROGENASE COMPLEX PDI- C2.BYSTRYKH SCP2 Q C2.REACTOME SARS COV 1 HOST INTERACTION C2.REACTOME PINK1 PRKN MEDIATED MITOPHAG C2.WP TRANSLATION FACTOF C2.WP TRANSLATION FACTOF C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO ANTEROGRADE AXONAL TRANSPOF C2.REACTOME RHOBTB1 GTPASE CYCL C2.REACTOME RHOBTB1 GTPASE CYCL C2.REACTOME RHO GTPASES ACTIVATE PAR C2.REACTOME DEGRADATION OF D C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT SOD1 TO PERK ATF4 SIGNALING PATHW, C2.REACTOME HSP90 CHAPERONE CYCLE FOR STEROID HORMONE RECEPTORS SHR IN THE PRESENCE OF LIGAN C2.WP OXIDATIVE PHOSPHORYLATIC C2.WP OXIDATIVE PHOSPHORYLATIC C2.REACTOME CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS ENDOSOME C2.REACTOME CROSS PRESENTATION OF SOLUBLE EXOGENOUS ANTIGENS ENDOSOME C2.REACTOME SIGNALING BY LTK IN CANCE C2.KEGG MEDICUS REFERENCE CA2 PYK2 RAS ERK SIGNALING PATHW, C2.JOHANSSON GLIOMAGENESIS BY PDGFB L C2.PIO ARF 3PATHW. C2.JOHANSSON GLIOMAGENESIS BY PDGFB L C2.PIO ARF 3PATHW.	HC TTL NS NS ST NS NS ST NS				
C2.ITO PTTG1 TARGETS I C2.REACTOME SUPPRESSION OF APOPTOS C2.KEGG MEDICUS REFERENCE ICOSLG ICOS PI3K SIGNALING PATHW. C2.BIOCARTA AT1R PATHW. C2.KEGG MEDICUS VARIANT MUTATION ACTIVATED EGFR TO RAS ERK SIGNALING PATHW. C2.KEGG MEDICUS VARIANT MUTATION ACTIVATED EGFR TO RAS ERK SIGNALING PATHW. C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT SNCA TO ANTEROGRADE AXONAL TRANSPORT C2.REACTOME RHO GTPASES ACTIVATE KTI C2.WP ELECTRON TRANSPORT CHAIN OXPHOS SYSTEM IN MITOCHONDR C2.REACTOME POST CHAPERONIN TUBULIN FOLDING PATHW. C2.REACTOME POST CHAPERONIN TUBULIN FOLDING PATHW. C2.REACTOME SCF SKP2 MEDIATED DEGRADATION OF P27 P. C2.WIEMANN TELOMERE SHORTENING AND CHRONIC LIVER DAMAGE I C2.REACTOME VLDLR INTERNALISATION AND DEGRADATIC C2.KEGG MEDICUS VARIANT TRK FUSION KINASE TO RAS ERK SIGNALING PATHW. C2.KEGG MEDICUS VARIANT TRK FUSION KINASE TO RAS ERK SIGNALING PATHW. C2.SIG REGULATION OF THE ACTIN CYTOSKELETON BY RHO GTPASE C2.NUTT GBM VS AO GLIOMA I C2.KEGG MEDICUS PATHOGEN ESCHERICHIA ESPJ TO IGG FCGR RAC SIGNALING PATHW. C2.WP MIR517 RELATIONSHIP WITH ARCN1 AND USI C2.KEGG MEDICUS REFERENCE RAB7 REGULATED MICROTUBULE MINUS END DIRECTED TRANSPOR	SIS AY				
C2.KEGG MEDICUS VARIANT AMPLIFIED FGFR TO RAS ERK SIGNALING PATHW. C2.WP 17P133 YWHAE COPY NUMBER VARIATIC C2.REACTOME RAF ACTIVATIC C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO ELECTRON TRANSFER IN COMPLE: C2.KEGG MEDICUS PATHOGEN SALMONELLA SOPB TO ARNO ARF ACTB G SIGNALING PATHW. C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO ANTEROGRADE AXONAL TRANSPOR C C2.DER IFN ALPHA RESPONSE I C2.KEGG MEDICUS REFERENCE PKA HOLOENZYM. C2.KEGG MEDICUS REFERENCE REGULATION OF GF RTK RAS ERK SIGNALING RAS UBIQUITINATION BY CUL3 COMPLE C2.PECE MAMMARY STEM CELL I C2.VERRECCHIA RESPONSE TO TGFB1 (C2.LAIHO COLORECTAL CANCER BOX4 II C2.LAIHO COLORECTAL CANCER SERRATED I C2.LAIHO COLORECTAL CANCER SERRATED I C2.KEGG MEDICUS VARIANT RET FUSION KINASE TO RAS ERK SIGNALING PATHW. C2.REACTOME NFE2L2 REGULATES PENTOSE PHOSPHATE PATHWAY GENE C2.WP INHIBITION OF EXOSOME BIOGENESIS AND SECRETION BY MANUMYCIN A IN CRPC CELL C2.LAIHO SENSITIVE VIA TSC1 AND TSC	DN DN X I X I X I X I X I X I X I X I X I X				
c2.KEGG MEDICUS ENV FACTOR E2 TO RAS ERK SIGNALING PATHW. c2.REACTOME SIGNAL ATTENUATIO c2.REACTOME PROLONGED ERK ACTIVATION EVEN' c2.KEGG MEDICUS PATHOGEN HBV LHBS TO PKC ERK SIGNALING PATHW, c2.REACTOME DEFECTIVE CFTR CAUSES CYSTIC FIBROS c2.VERRECCHIA EARLY RESPONSE TO TGFI c2.KEGG OXIDATIVE PHOSPHORYLATIC c2.KEGG MEDICUS REFERENCE KITLG KIT RAS ERK SIGNALING PATHW, c2.KEGG MEDICUS VARIANT MUTATION ACTIVATED KIT TO RAS ERK SIGNALING PATHW, c2.REACTOME ATF6 ATF6 ALPHA ACTIVATES CHAPERONE GENE c2.PID PRL SIGNALING EVENTS PATHW, c2.KEGG MEDICUS VARIANT EML4 ALK FUSION KINASE TO RAS ERK SIGNALING PATHW, c2.REACTOME DEFECTIVE CHSTS CAUSES SEDC. c2.REACTOME DEFECTIVE CHSTS CAUSES SEDC. c2.REACTOME SEALING OF THE NUCLEAR ENVELOPE NE BY ESCRT c2.REACTOME CONSTITUTIVE SIGNALING BY EGFRV, c2.REACTOME CONSTITUTIVE SIGNALING PATHW, c2.REACTOME PDH COMPLEX SYNTHESIZES ACETYL COA FROM PO c2.REACTOME COPI MEDIATED ANTEROGRADE TRANSPOR c2.REACTOME COPI MEDIATED ANTEROGRADE TRANSPOR c2.REACTOME ACTIVATION OF RAC1 DOWNSTREAM OF NMDAF	AY DN TS AY AY BIS B1 DN AY AY ES AY AY IIII IIII IIII AY YR RT RT RS PS				
c2.REACTOME ACTIVATION OF RAC1 DOWNSTREAM OF NMDAR c2.REACTOME REGULATION OF RAS BY GAR c2.REACTOME REGULATION OF RAS BY GAR c2.REACTOME ON NF1 LOSS OF FUNCTION VARIANT c2.REACTOME CALNEXIN CALRETICULIN CYCI c2.UNTERMAN PROGRESSIVE VS STABLE IPF NK CELL U c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO ELECTRON TRANSFER IN COMPLEX c2.REACTOME CELL EXTRACELLULAR MATRIX INTERACTION c2.REACTOME INTERLEUKIN 12 SIGNALIN c2.REACTOME LOSS OF MECP2 BINDING ABILITY TO THE NCOR SMRT COMPLEX c2.MOOTHA VOXPHC c2.PARK HSC VS MULTIPOTENT PROGENITORS U c2.KEGG MEDICUS REFERENCE TGFA EGFR RAS ERK SIGNALING PATHW. c2.KEGG MEDICUS REFERENCE TGFA EGFR RAS ERK SIGNALING PATHW. c2.WP HEPATOCYTE GROWTH FACTOR RECEPTOR SIGNALIN c2.JI RESPONSE TO FSH E c2.REACTOME CELLULAR RESPONSE TO HYPOX c2.REACTOME RETROGRADE NEUROTROPHIN SIGNALLIN c2.APRELIKOVA BRCA1 TARGE: c2.PID RANBP2 PATHW. c2.KEGG VIBRIO CHOLERAE INFECTIC	RS PS PS UP IV NS NG EX DS UP AY ON ON KIA NG ON KIA NG ON KIA NG ON KIA NG ON				
C2.KEGG VIBRIO CHOLERAE INFECTIC C2.REACTOME PTK6 EXPRESSIO C2.REACTOME N GLYCAN TRIMMING IN THE ER AND CALNEXIN CALRETICULIN CYCI C2.BIOCARTA SAM68 PATHW. C2.KEGG MEDICUS PATHOGEN HBV HBX TO ERK SIGNALING PATHW. C2.REACTOME DEFECTIVE CHST14 CAUSES EDS MUSCULOCONTRACTURAL TYF C2.REACTOME LRR FLII INTERACTING PROTEIN 1 LRRFIP1 ACTIVATES TYPE I IFN PRODUCTIC C2.PID FAK PATHW. C2.PID FAK PATHW. C2.DAZARD UV RESPONSE CLUSTER C C2.REACTOME RESPONSE OF MTB TO PHAGOCYTOS C2.KEGG MEDICUS PATHOGEN SHIGELLA IPAA TO ITGA B RHOGEF RHOA SIGNALING PATHW. C2.KEGG MEDICUS REFERENCE P4 PR RAS ERK SIGNALING PATHW. C2.REACTOME RHO GTPASES ACTIVATE WASPS AND WAYE C2.HERNANDEZ ABERRANT MITOSIS BY DOCETACEL 4NM E C2.ALONSO METASTASIS EMT L C2.KEGG MEDICUS VARIANT MUTATION ACTIVATED MET TO RAS ERK SIGNALING PATHW. C2.PID ECADHERIN NASCENT AJ PATHW. C2.BIOCARTA RAN PATHW.	DN DN LE AY AY PE DN AY AY AY G4 G4 G5IS AY AY AY AY AY AY AY AY AY				
C2.KEGG MEDICUS VARIANT MET OVEREXPRESSION TO RAS ERK SIGNALING PATHW, C2.KEGG PATHOGENIC ESCHERICHIA COLI INFECTIC C2.WP C2.KEGG MEDICUS REFERENCE TIGHT JUNCTION ACTIN SIGNALING PATHW, C2.MATZUK FERTILIZATIC C2.WP WNTBETACATENIN SIGNALING INHIBITORS IN CURRENT AND PAST CLINICAL TRIAI C2.WP ARSENIC METABOLISM AND REACTIVE OXYGEN SPECIES GENERATIC C2.BIOCARTA RAB PATHW, C2.KEGG MEDICUS REFERENCE COHESIN LOADIN C2.KEGG MEDICUS REFERENCE COHESIN LOADIN C2.KEGG MEDICUS REFERENCE FIT3LG FLT3 RAS ERK SIGNALING PATHW, C2.KEGG MEDICUS VARIANT DUPLICATION OR MUTATION ACTIVATED FLT3 TO RAS ERK SIGNALING PATHW, C2.KEGG MEDICUS VARIANT IGF2 OVEREXPRESSION TO RAS ERK SIGNALING PATHW, C2.GALE APL WITH FLT3 MUTATED IC C2.REACTOME ARYL HYDROCARBON RECEPTOR SIGNALLIN C2.ZHAN VARIABLE EARLY DIFFERENTIATION GENES IC C2.WANG TUMOR INVASIVENESS IC C2.WANG TUMOR INVASIVENESS IC C2.REACTOME MAPK3 ERK1 ACTIVATION	AY ON ON ON ON ON AY ON AY ON AY NG AY ON				
c2.KEGG MEDICUS PATHOGEN HPV E5 TO ANTIGEN PROCESSING AND PRESENTATION BY MHC CLASS I MOLECULE C2.PELLICCIOTTA HDAC IN ANTIGEN PRESENTATION IN C2.PELLICCIOTTA HDAC IN ANTIGEN PRESENTATION IN C2.PID BETA CATENIN DEG PATHW. C2.PID BETA CATENIN DEG PATHW. C2.PID BETA CATENIN DEG PATHW. C2.BIOCARTA IFNG PATHW. C2.BIOCARTA IFNG PATHW. C2.REACTOME REGULATION OF PTEN STABILITY AND ACTIVITY OF MATERNALL MRNAS BY MATERNALLY STORED FACTOF C2.REACTOME M DECAY DEGRADATION OF MATERNAL MRNAS BY MATERNALLY STORED FACTOF C2.REACTOME SYNTHESIS OF ACTIVE UBIQUITIN ROLES OF E1 AND E2 ENZYME C2.WP 20211 COPY NUMBER VARIATION SYNDROM C2.REACTOME INTERLEUKIN 6 SIGNALIN C2.WP 20211 COPY NUMBER VARIATION SYNDROM C2.REACTOME INTERLEUKIN 6 SIGNALIN C2.REACTOME INTERLEUKIN 6 SIGNALIN C2.REACTOME APOBECSON MEDIATED RESISTANCE TO HIV 1 INFECTION C2.REACTOME CS DS DEGRADATION C2.REACTOME APOBECSON MEDIATED RESISTANCE TO HIV 1 INFECTION C2.BIOCARTA CREB PATHW, C2.REACTOME APOBECSON MEDIATED RESISTANCE TO HIV 1 INFECTION C2.REACTOME HEDGEHOG LIGAND BIOGENES C2.REACTOME HEDGEHOG LIGAND BIOGENES C2.REACTOME HEDGEHOG LIGAND BIOGENES C2.REACTOME DECTIN 1 MEDIATED NONCANONICAL NF KB SIGNALIN	DN DN AY				
c2.IGLESIAS E2F TARGETS U c2.BIOCARTA SALMONBLLA PATHW c2.REACTOME INTERLEUKIN 12 FAMILY SIGNALIN c2.REACTOME SOS MEDIATED SIGNALIN c2.CAFFAREL RESPONSE TO THC 8HR 3 I c2.REACTOME METABOLISM OF POLYAMINE c2.PID NETRIN PATHW c2.BIOCARTA VDR PATHW c2.BIOCARTA VDR PATHW c2.KEGG MEDICUS REFERENCE ELECTRON TRANSFER IN COMPLEX c2.REACTOME CALCINEURIN ACTIVATES NF c2.REACTOME CALCINEURIN ACTIVATES NF c2.REACTOME MATURATION OF SARS COV 2 SPIKE PROTE c2.REACTOME MATURATION OF SARS COV 2 SPIKE PROTE c2.REACTOME REGULATION OF BACH 1 ACTIVI c2.BERENJENO ROCK SIGNALING NOT VIA RHOA I c2.WP AEROBIC GLYCOLYSIS AUGMENTE c2.REACTOME ATF6 ATF6 ALPHA ACTIVATES CHAPERONE c2.VERRECCHIA RESPONSE TO TGFB1 c2.ZHONG SECRETOME OF LUNG CANCER AND FIBROBLAS	AY NG NG DN ES AY AY IV CAT DN AY EIN TTY DN ED ES C2 ST				
C2.JIANG AGING CEREBRAL CORTEX I C2.REACTOME SIGNALING BY ERBB2 ECD MUTAN I C2.PID NCADHERIN PATHW. C2.REACTOME DOWNREGULATION OF SMAD2 3 SMAD4 TRANSCRIPTIONAL ACTIVI C2.WP TGFB SMAD SIGNALIN C2.KEGG MEDICUS PATHOGEN ARSENIC TO ELECTRON TRANSFER IN COMPLEX C2.REACTOME REGULATION OF MRNA STABILITY BY PROTEINS THAT BIND AU RICH ELEMEN C2.KEGG MEDICUS REFERENCE IGF IGF1R RAS ERK SIGNALING PATHW. C2.REACTOME CHAPERONE MEDIATED AUTOPHAC C2.LEIN ASTROCYTE MARKEF C2.BIOCARTA PRION PATHW. C2.KEGG MEDICUS REFERENCE AREG EGFR RAS ERK SIGNALING PATHW. C2.KEGG MEDICUS REFERENCE AREG EGFR RAS ERK SIGNALING PATHW. C2.HEIDENBLAD AMPLIFIED IN BONE CANCE C2.BELMOHSEN ELAVL4 TARGE C2.LI AMPLIFIED IN LUNG CANCE C2.BAZARD UV RESPONSE CLUSTER (C2.PID ERBB1 RECEPTOR PROXIMAL PATHW. C2.PID ERBB1 RECEPTOR PROXIMAL PATHW. C2.REACTOME JOSEPHIN DOMAIN DUR	TS AY TY NG K III TS AY				
C2.REACTOME MAP3K8 TPL2 DEPENDENT MAPK1 3 ACTIVATION C2.KEGG MEDICUS REFERENCE EREG EGFR RAS ERK SIGNALING PATHWOM C2.KIM BIPOLAR DISORDER OLIGODENDROCYTE DENSITY CORR I C2.ZHANG PROLIFERATING VS QUIESCEN C2.REACTOME G1 S DNA DAMAGE CHECKPOINT C2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER C2.KAPOSI LIVER CANCER MET I C2.REACTOME INLB MEDIATED ENTRY OF LISTERIA MONOCYTOGENES INTO HOST CE C2.KEGG MEDICUS REFERENCE LYSOSOMAL CA2 RELEAS C2.HOLLEMAN PREDNISOLONE RESISTANCE B ALL I C2.REACTOME RHO GTPASES ACTIVATE C C2.REACTOME TRANSLOCATION OF SLC2A4 GLUT4 TO THE PLASMA MEMBRAY C2.DASU IL6 SIGNALING SCAR I C2.BIOCARTA CCR3 PATHWOM C2.DASU IL6 SIGNALING SCAR I C2.REACTOME ESTROGEN STIMULATED SIGNALING THROUGH PRKO C2.ABRAMSON INTERACT WITH AIR C2.WP DISORDERS IN KETOLYS C2.CHEN LUNG CANCER SURVIVI	AY UP NT TS 10 UP LLL SE UP CIT NE AY ON AY ON CZ CZ CZ CZ CR RE SIS				
c2.KEGG MEDICUS REFERENCE PP2A AKT SIGNALING PATHW. c2.BIOCARTA IGF1R PATHW. c2.KEGG MEDICUS REFERENCE EGF EGFR RAS ERK SIGNALING PATHW. c2.KEGG MEDICUS REFERENCE EGF EGFR RAS ERK SIGNALING PATHW. c2.KEGG MEDICUS REFERENCE EGF EGFR RAS ERK SIGNALING PATHW. c2.PID S1P S1P2 PATHW. c2.REACTOME DRUG MEDIATED INHIBITION OF CDK4 CDK6 ACTIVITY. c2.KEGG MEDICUS PATHOGEN HTLV 1 TAX TO TNF JNK SIGNALING PATHW. c2.HU ANGIOGENESIS EGT. c2.REACTOME DOWNSTREAM SIGNALING EVENTS OF B CELL RECEPTOR BOTH CASES OF A CAS	UP AY AY AY TY SE AY ON CR ET UP AY AY AY BEX AY BEX AY BEX BES BE				
c2.ZHONG SECRETOME OF LUNG CANCER AND ENDOTHELIL c2.BIOCARTA MET PATHW. c2.BIZUKA LIVER CANCER EARLY RECURRENG c2.LEIN OLIGODENDROCYTE MARKEF c2.WP PDGF PATHW. c2.REACTOME SELECTIVE AUTOPHAG c2.VERRECCHIA RESPONSE TO TGFB1 c2.REACTOME REGULATION OF GENE EXPRESSION BY HYPOXIA INDUCIBLE FACTO c2.CHNG MULTIPLE MYELOMA HYPERPLOID DE c2.DEMAGALHAES AGING LE c2.WP LDLRAD4 AND WHAT WE KNOW ABOUT c2.VISALA AGING LYMPHOCYTE LE c2.TIEN INTESTINE PROBIOTICS 24HR DE c2.REACTOME NEF MEDIATED CO4 DOWN REGULATION c2.REACTOME MAPK6 MAPK4 SIGNALING c2.REACTOME MAPK6 MAPK4 SIGNALING c2.REACTOME MAPK6 MAPK4 SIGNALING c2.REACTOME SIGNALING BY NOTCH c2.FLECHNER BIOPSY KIDNEY TRANSPLANT OK VS DONOR LE c2.TCGA GLIOBLASTOMA MUTATE c2.TCGA GLIOBLASTOMA MUTATE c2.TCGA GLIOBLASTOMA MUTATE	JM AY AY CE RS AY GY C4 DR DN UP UP DN ON NG H4 UP ES				
C2.REACTOME ACTIVATION OF BAD AND TRANSLOCATION TO MITOCHONDR C2.REACTOME SIGNAL REGULATORY PROTEIN FAMILY INTERACTION C2.BIOCARTA AGPCR PATHW, C2.NATSUME RESPONSE TO INTERFERON BETA I C2.REACTOME SUPPRESSION OF PHAGOSOMAL MATURATIO C2.REACTOME SUPPRESSION OF PHAGOSOMAL MATURATIO C2.REACTOME REGULATION OF ENDOGENOUS RETROELEMENTS BY KRAB ZFP PROTEIN C2.BIOCARTA INTEGRIN PATHW, C2.REACTOME SIGNAL TRANSDUCTION BY C2.BIOCARTA SIGNAL TRANSDUCTION BY C2.KEGG MEDICUS REFERENCE PINK PARKIN MEDIATED AUTOPHAGOSOME FORMATIC C2.BIOCARTA BARRESTIN PATHW, C2.KEGG MEDICUS PATHOGEN SALMONELLA SOPB TO RHOA SIGNALING PATHW, C2.KEGG MEDICUS PATHOGEN SALMONELLA SOPB TO RHOA SIGNALING PATHW, C2.REACTOME IRAK1 RECRUITS IKK COMPLUCATION C2.BIOCARTA IDENTIFY OF ENDOTHELIAL CELLS VIA CYTOSKELETON REARRANGEMEN C2.WP MFAP5 EFFECT ON PERMEABILITY AND MOTILITY OF ENDOTHELIAL CELLS VIA CYTOSKELETON REARRANGEMEN C2.REACTOME MET ACTIVATES RAP1 AND RACE.	KC NS NS AY DN DN NS AY L1 AY DN AY AY AY AY AY AY AY AY AY NS AY NS NS NS NS NS NS NS NS NS NS NS NS NS				patho_cat_name • Nerve sheath tumors Spindle and epithelioid tumors
c2.REACTOME SOMITOGENES c2.REACTOME SUMO IS TRANSFERRED FROM E1 TO E2 UBE2I UBE c2.ANDERSEN LIVER CANCER KRT19 I c2.BARIS THYROID CANCER I c2.BARIS THYROID CANCER I c2.WIERENGA PML INTERACTOM c2.WP MITOCHONDRIAL FATTY ACID SYNTHESIS AND RESPIRATIC c2.KEGG MEDICUS VARIANT HRAS OVEREXPRESSION TO ERK SIGNALING PATHW, c2.SCIAN INVERSED TARGETS OF TP53 AND TP73 I c2.AKL HTLV1 INFECTION I c2.BIOCARTA CXCR4 PATHW, c2.PARK HSC VS MULTIPOTENT PROGENITORS I c2.KEGG MEDICUS REFERENCE REGULATION OF GF RTK RAS ERK SIGNALING PATHWAY ADAPTOR PROTEIN c2.REACTOME ACTIVATION OF THE AP 1 FAMILY OF TRANSCRIPTION FACTOR c2.KEGG MEDICUS REFERENCE REGULATION SEFERENCE BETA OXIDATION PEROXISOME VLCI c2.POMEROY MEDULLOBLASTOMA PROGNOSIS I c2.KEGG MEDICUS PATHOGEN HIV VPR TAT TO TNF JNK SIGNALING PATHWAY c2.KEGG MEDICUS PATHOGEN HIV VPR TAT TO TNF JNK SIGNALING PATHWAY c3.PERCATOME PROCENTIAL PROCESSION AND PLANSORY.	C9 UP UP AY ME DN AY DN UP AY ON UP AY ON SAY DN ON				 Gliomas Glioneuronal tumors
C2.REACTOME REGULATION OF CDH19 EXPRESSION AND FUNCTIC C2.BILANGES SERUM SENSITIVE VIA TSC C2.REACTOME APC C CDH1 MEDIATED DEGRADATION OF CDC20 AND OTHER APC C CDH1 TARGETED PROTEINS IN LATE MITOSIS EARLY (C2.BIOCARTA STAT3 PATHW, C2.REACTOME ANTIGEN PRESENTATION FOLDING ASSEMBLY AND PEPTIDE LOADING OF CLASS I MIT C2.KEDA MIR1 TARGETS L C2.KEGG MEDICUS VARIANT MUTATION INACTIVATED P62 TO PINK PARKIN MEDIATED AUTOPHAGOSOME FORMATIC C2.MOREIRA RESPONSE TO TSA L C2.WP PARKINUBIQUITIN PROTEASOMAL SYSTEM PATHW, C2.KOBAYASHI EGFR SIGNALING 6HR L C2.REACTOME BETA OXIDATION OF LAUROYL COA TO DECANOYL COA CC C2.PID ECADHERIN KERATINOCYTE PATHW, C2.REACTOME UPTAKE AND FUNCTION OF ANTHRAX TOXIN C2.PID ERB GENOMIC PATHW, C2.SESTO RESPONSE TO UV (C2.SEIDCARTA GPCR PATHW, C2.SEIDCARTA GPCR PATHW, C2.SEIDCARTA GPCR PATHW, C2.SEIDCARTA RACCYCD PATHW, C2.SEIDCARTA RACCYCD PATHW, C2.BIOCARTA RACCYCD PATHW, C3.BIOCARTA RACCYCD PATHW, C4.BIOCARTA RACCYCD PATHW, C4.BIOCARTA RACCYCD PATHW, C5.BIOCARTA RACCYCD PATHW, C5.BIOCARTA RACCYCD PATHW, C6.BIOCARTA RACCYCD PATHW, C6.BIOCARTA RACCYCD PATHW, C7.BIOCARTA RACCYCD PATHW, C7.BIOCA	C2 G1 AY HC UP DN UP AY AY AY AY AY UP CA AY				
C2.REACTOME REGULATION OF TP53 ACTIVITY THROUGH METHYLATIC C2.REACTOME NUCLEAR EVENTS MEDIATED BY NFE2 C2.BIOCARTA MYOSIN PATHW. C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT SNCA TO PERK ATF4 SIGNALING PATHW. C2.REACTOME SARS COV 1 INFECTIO C2.KEGG MEDICUS VARIANT MUTATION ACTIVATED EGFR TO PLCG ERK SIGNALING PATHW. C2.TIMOFEEVA GROWTH STRESS VIA STAT1 I C2.KEGG MEDICUS REFERENCE TYPE II INTERFERON TO JAK STAT SIGNALING PATHW. C2.IBRAHIM NRF3 I C2.WP PAFAH1B1 COPY NUMBER VARIATIO C2.MARTINEZ RESPONSE TO TRABECTEDIN I C2.REACTOME SIGNALING BY FGFI C2.KIM ALL DISORDERS CALB1 CORR I C2.PID AR NONGENOMIC PATHW. C2.REACTOME MHC CLASS II ANTIGEN PRESENTATIO C2.KEGG MEDICUS REFERENCE HGF MET RAS ERK SIGNALING PATHW. C2.KEGG MEDICUS REFERENCE HGF MET RAS ERK SIGNALING PATHW. C2.WP EFFECT OF PROGERIN ON GENES INVOLVED IN PROGER C2.HOFMANN MYELODYSPLASTIC SYNDROM LOW RISK I	ON IL2 AY AY ON AY ON AY ON				
C2.REACTOME SIGNALING BY PDGFR IN DISEAS C2.GUILLAUMOND KLF10 TARGETS I C2.WP HIJACK OF UBIQUITINATION BY SARSCO C2.REACTOME CLEC7A DECTIN 1 INDUCES NFAT ACTIVATIO C2.CAFFAREL RESPONSE TO THC 8HR 5 U C2.WP GNAQ PATHWAYS IN PORTWINE STA C2.REACTOME INFECTION WITH MYCOBACTERIUM TUBERCULOS C2.CHEOK RESPONSE TO MERCAPTOPURINE AND LD MTX U C2.GALIE TUMOR STEMNESS GENE C2.REACTOME MIRO GTPASE CYCI C2.REACTOME LOSS OF FUNCTION OF MECP2 IN RETT SYNDROM C2.MARIADASON RESPONSE TO BUTYRATE CURCUMIN SULINDAC TSA C2.MCBRYAN PUBERTAL BREAST 5 6WK I C2.PID IGF1 PATHW, C2.HEDENFALK BREAST CANCER BRACX U C2.KEGG MEDICUS REFERENCE MICROTUBULE DEPOLYMERIZATIO C2.KYNG ENVIRONMENTAL STRESS RESPONSE U C2.PID EPHB FWD PATHW, C2.PID EPHB FWD PATHW,	DN V2 DN UP UP UIN UIP				
c2.KEGG PRION DISEASE c2.KEGG MEDICUS REFERENCE ARL8 REGULATED MICROTUBULE PLUS END DIRECTED TRANSPOR c2.ZHONG SECRETOME OF LUNG CANCER AND MACROPHAG c2.REACTOME SIGNALING BY EGFR IN CANCE c2.ZHANG ADIPOGENESIS BY BMI c2.REACTOME TYSND1 CLEAVES PEROXISOMAL PROTEIN c2.BIOCARTA HCMV PATHW. c2.REACTOME FCERI MEDIATED NF KB ACTIVATIC c2.YAMASHITA LIVER CANCER WITH EPCAM L c2.SIG INSULIN RECEPTOR PATHWAY IN CARDIAC MYOCYTE c2.BIOCARTA S1P PATHW. c2.PID ERBB2 ERBB3 PATHW. c2.PID ERBB2 ERBB3 PATHW. c2.KEGG MEDICUS REFERENCE BMP9 10 SIGNALING PATHW. c2.CROMER METASTASIS I c2.REACTOME ASYMMETRIC LOCALIZATION OF PCP PROTEIN c2.KOHN EMT MESENCHYM. c2.WP ALPHA 6 BETA 4 SIGNALIN c2.BIOCARTA BARRESTIN SRC PATHW. c2.CHAUHAN RESPONSE TO METHOXYESTRADIOL L	RT GE ER P7 NS AY DN UP ES AY AY AY AY UP NS AL				
c2.REACTOME RHOT1 GTPASE CYCL c2.LEE AGING NEOCORTEX. c2.BIOCARTA RAS PATHW. c2.WP AFLATOXIN B1 METABOLIS c2.MRLI PSEUDOPOD c2.REACTOME GOLGI TO ER RETROGRADE TRANSPOF c2.REACTOME NF KB IS ACTIVATED AND SIGNALS SURVIV. c2.PID PDGFRB PATHW. c2.REACTOME DOWNSTREAM SIGNAL TRANSDUCTIC c2.WP ESTROGEN SIGNALIN c2.WP ESTROGEN SIGNALIN c2.WP ANDROGEN RECEPTOR SIGNALIN c2.REACTOME ER TO GOLGI ANTEROGRADE TRANSPOF c2.KUROKAWA LIVER CANCER EARLY RECURRENCE I c2.REACTOME TRANSFERIN ENDOCYTOSIS AND RECYCLIN c2.PID ARF6 DOWNSTREAM PATHW. c2.REACTOME UPTAKE AND ACTIONS OF BACTERIAL TOXIC c2.WELCSH BRCA1 TARGETS I c2.WELCSH BRCA1 TARGETS I c2.BIOCARTA RECK PATHW.	UP AY AY AY DIA RT AL AY DIN NG				
c2.KEGG MEDICUS VARIANT OLIGOMERIC CONFORMATION PRPC TO ANTEROGRADE AXONAL TRANSPOR c2.PID PDGFRA PATHW. c2.REACTOME ERKS ARE INACTIVATE c2.PID MET PATHW. c2.WP MAPK CASCAL c2.KEGG MEDICUS PATHOGEN SHIGELLA IPGB1 TO ITGA B RHOG RAC SIGNALING PATHW. c2.REACTOME ABC TRANSPORTER DISORDEF c2.REACTOME ABC TRANSPORTER DISORDEF c2.REACTOME REGULATION OF LOCALIZATION OF FOXO TRANSCRIPTION FACTOR c2.REACTOME EPHB MEDIATED FORWARD SIGNALIN c2.CHOI ATL STAGE PREDICTO c2.JISON SICKLE CELL DISEASE I c2.REACTOME ACTIVATION OF AMPK DOWNSTREAM OF NMDAF c2.REACTOME LISTERIA MONOCYTOGENES ENTRY INTO HOST CELI c2.BIOCARTA EGF PATHW. c2.REACTOME RUNX1 REGULATES TRANSCRIPTION OF GENES INVOLVED IN DIFFERENTIATION OF HSC c2.WATANABE RECTAL CANCER RADIOTHERAPY RESPONSIVE I c2.KEGG EPITHELIAL CELL SIGNALING IN HELICOBACTER PYLORI INFECTIO c2.KEGG SPLICEOSON c2.BORCZUK MALIGANAT MESOTHELIOMA c2.JOSEPH RESPONSE TO SODIUM BUTYRATE I	AY ED AY AY OP AY OP AY OP AN AY OP AN AY AN AY CS DN ON				
c2.REACTOME REGULATION OF RUNX2 EXPRESSION AND ACTIVITY c2.MMS MOUSE LYMPH HIGH 4HRS U c2.BIOCARTA CARM1 PATHW. c2.REACTOME NEGATIVE REGULATION OF FGFR4 SIGNALIN c2.WP INTERACTOME OF POLYCOMB REPRESSIVE COMPLEX 2 PRO c2.REACTOME SYNDECAN INTERACTION c2.BURTON ADIPOGENESIS c2.KEGG MEDICUS VARIANT MUTATION INACTIVATED SIGMAR1 TO CA2 APOPTOTIC PATHW. c2.REACTOME GP1B IX V ACTIVATION SIGNALLIN c2.DORSAM HOXA9 TARGETS U c2.NUTT GBM VS AO GLIOMA U c2.KEGG MEDICUS REFERENCE COPII VESICLE FORMATIC c2.KEGG MEDICUS REFERENCE COPII VESICLE FORMATIC c2.KEGG MEDICUS REFERENCE EGF ERBB2 RAS ERK SIGNALING PATHW. c2.REACTOME BETA CATENIN PHOSPHORYLATION CASCAL c2.KEGG VASOPRESSIN REGULATED WATER REABSORPTIC c2.DITTMER PTHLH TARGETS U c2.PID ERBB1 DOWNSTREAM PATHW. c2.PID MTOR 4PATHW. c2.PID MTOR 4PATHW. c2.PID MTOR 4PATHW.	TY UP AY AY NG C2 NS 11 AY NG UP DN AY ON AY ON AY DE DN				
c2.PID INSULIN GLUCOSE PATHW. c2.SWEET KAS ONCOGENIC SIGNATU c2.REACTOME ER QUALITY CONTROL COMPARTMENT ERC c2.POMEROY MEDULLOBLASTOMA DESMOPLASIC VS CLASSIC I c2.BIOCARTA PITX2 PATHW. c2.PID PI3K PLC TRK PATHW. c2.PID PI3K PLC TRK PATHW. c2.REACTOME SYNTHESIS OF PIPS AT THE ER MEMBRAN c2.PID FOXO PATHW. c2.BIOCARTA CTBP1 PATHW. c2.BIOCARTA CTBP1 PATHW. c2.BIOCARTA TRKA PATHW. c2.BIOCARTA TRKA PATHW. c2.BIOCARTA BIOPEPTIDES PATHW. c2.BIOCARTA BIOPEPTIDES PATHW. c2.KEGG MEDICUS VARIANT AMPLIFIED PDGFR TO PLCG CAMK SIGNALING PATHW. c2.REACTOME UCH PROTEINASI c2.WP PHYSIOLOGICAL AND PATHOLOGICAL HYPERTROPHY OF THE HEAR c2.WANG TUMOR INVASIVENESS I c2.MYLLYKANGAS AMPLIFICATION HOT SPOT c2.KEACTOME DARPP 32 EVENT	RE QC DDN AY				
c2.REACTOME DOWNREGULATION OF TGF BETA RECEPTOR SIGNALIN c2.SA PTEN PATHW. c2.PID VEGFR1 2 PATHW. c2.PID TCR RAS PATHW. c2.GENTILE UV RESPONSE CLUSTER I c2.REACTOME VEGFR2 MEDIATED CELL PROLIFERATIC c2.LUND SILENCED BY METHYLATIC c2.PID SMAD2 3PATHW. c2.PID SMAD2 3PATHW. c2.PID SYNDECAN 3 PATHW. c2.PID SYNDECAN 3 PATHW. c2.WP MET IN TYPE 1 PAPILLARY RENAL CELL CARCINON c2.KEGG MEDICUS REFERENCE MAGI PTEN SIGNALING PATHW. c2.ZHOU TNF SIGNALING 30M c2.JIANG MELANOMA TRM3 CI c2.KAAB FAILED HEART ATRIUM c2.PECE MAMMARY STEM CELL C c2.REACTOME ORC1 REMOVAL FROM CHROMAT c2.REACTOME DEADENYLATION OF MRI c2.BICCORRES c2.REACTOME DEADENYLATION OF MRI	NG AY AY AY D8 DN DN AY AY AY AY AY AY BS MA AY AY IIIN D8 DN				
C2.WP THYROID STIMULATING HORMONE TSH SIGNALIN C2.WP BILE ACID SYNTHESIS AND ENTEROHEPATIC CIRCULATIC C2.WP PDGFRBETA PATHW. C2.BIOCARTA EPONFKB PATHW. C2.BIOCARTA EPONFKB PATHW. C2.BIOCARTA IEFONFKB PATHW. C2.BIOCARTA IGF1 PATHW. C2.BIOCARTA IGF1 PATHW. C2.BIOCARTA PTDINS PATHW. C2.KARLSSON TGFB1 TARGETS IC C2.BIOCARTA CDMAC PATHW. C2.BIOCARTA CDMAC PATHW. C2.BIOCARTA CDMAC PATHW. C2.BIOCARTA PELP1 PATHW. C2.BIOCARTA PELP1 PATHW. C2.IIZUKA LIVER CANCER PROGRESSION L1 G1 IC C2.REACTOME SIGNALLING TO ERE C2.WP VASOPRESSINREGULATED WATER REABSORPTIC C2.NAM FXYD5 TARGETS IC C2.REACTOME TGF BETA RECEPTOR SIGNALING ACTIVATES SMAL C2.KEGG MEDICUS ENV FACTOR ARSENIC TO ELECTRON TRANSFER IN COMPLEX C2.REACTOME FORMATION OF PARAXIAL MESODER C2.REACTOME PCP CE PATHW. C2.REACTOME PCP CE PATHW.	ON AY				
C2.REACTOME ACTIVATED NTRK2 SIGNALS THROUGH RECORD C3. REACTOME ACTIVATED NTRK2 SIGNALS THROUGH RECORD C3. REACTOME ACTIVATED NTRK2 SIGNALS THROUGH RECORD C3. REACTOME ACTIVATED NTRK2 SIGNALS THROUGH RECORD C3. RETURN C4. PETRETTO CARDIAC HYPERTROPH C2. KEGG MEDICUS ENV FACTOR METALS TO JNK SIGNALING PATHW. C2. BIOCARTA AKAP95 PATHW. C3. DAVICIONI RHABDOMYOSARCOMA PAX FOXO1 FUSION E C4. WATANABE RECTAL CANCER RADIOTHERAPY RESPONSIVE LECT. C5. BIOCARTA MAL PATHW. C5. PID S1P S1P3 PATHW. C5. PID S1P S1P3 PATHW. C5. REACTOME FORMYL PEPTIDE RECEPTORS BIND FORMYL PEPTIDES AND MANY OTHER LIGAND C5. REACTOME REGULATION OF CYTOSKELETAL REMODELING AND CELL SPREADING BY IPP COMPLEX COMPONENT C5. REACTOME REGULATION OF CYTOSKELETAL REMODELING AND CELL SPREADING BY IPP COMPLEX COMPONENT C5. REACTOME BACTERIAL INFECTION PATHWAY C5. SEACTOME BACTERIAL INFECTION PATHWAY C5. SYED ESTRADIOL RESPONSE	AS DN HY				
C2.REACTOME SIGNALING BY FGFI C2.PID ILK PATHW, C2.WILSON PROTEASES AT TUMOR BONE INTERFACE U C2.BIOCARTA HIF PATHW, C2.REACTOME ENOS ACTIVATIO C2.DANG MYC TARGETS I C2.COLIN PILOCYTIC ASTROCYTOMA VS GLIOBLASTOMA I C2.SANA RESPONSE TO IFNG I C2.ACOSTA LOW DOSE UV RESPONSE VIA ERCC3 XPCS I C2.REACTOME SEMA4D INDUCED CELL MIGRATION AND GROWTH CONE COLLAPS C2.DACOSTA LOW DOSE UV RESPONSE VIA ERCC3 XPCS I C2.REACTOME BETA OXIDATION OF OCTANOYL COA TO HEXANOYL COC C2.REACTOME GOLGI ASSOCIATED VESICLE BIOGENES C2.REACTOME POST TRANSCRIPTIONAL SILENCING BY SMALL RNA C2.PID ERBB1 INTERNALIZATION PATHWA C2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT ABETA TO IRETA JNK SIGNALING PATHWA C2.REACTOME PTEN REGULATIO C2.WP IL6 SIGNALING C2.WP IL6 SIGNALING C2.OUELLET OVARIAN CANCER INVASIVE VS LMP I	R3 AY UP AY ON ON ON SE ON OA SIS SIS SIS SIS AS AY AY AY AY AY AY ON				
c2.SIMBULAN PARP1 TARGETS U c2.KEGG MEDICUS REFERENCE EGF EGFR RAS RALGDS SIGNALING PATHW. c2.HASLINGER B CLL WITH 6Q21 DELETIC c2.REACTOME TRANSCRIPTIONAL REGULATION BY RUN; c2.REACTOME SEMA4D IN SEMAPHORIN SIGNALIN c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT PSEN1 TO ANTEROGRADE AXONAL TRANSPOP c2.KEGG MEDICUS PATHOGEN SALMONELLA SPVD TO TNF NFKB SIGNALING PATHW, c2.MEINHOLD OVARIAN CANCER LOW GRADE I c2.JIANG MELANOMA TRM8 CI c2.JIANG MELANOMA TRM8 CI c2.REACTOME SIGNALING BY TGF BETA RECEPTOR COMPLEX IN CANCE c2.REACTOME SIGNALING BY TGF BETA RECEPTOR COMPLEX IN CANCE c2.REACTOME SCAVENGING BY CLASS A RECEPTOR c2.REACTOME SCAVENGING BY CLASS A RECEPTOR c2.REACTOME CYCLIN A CDK2 ASSOCIATED EVENTS AT S PHASE ENTI- c2.WP NCRNAS INVOLVED IN STAT3 SIGNALING IN HEPATOCELLULAR CARCINOM c2.KEGG MEDICUS VARIANT EML4 ALK FUSION KINASE TO PLCG ERK SIGNALING PATHW c2.REACTOME ARMS MEDIATED ACTIVATIC c2.REACTOME ARMS MEDIATED ACTIVATIC c2.REACTOME ARMS MEDIATED ACTIVATIC	UP U				
c2.KEGG MEDICUS PATHOGEN HCMV US27 TO CXCR4 GNB G PLCB PKC SIGNALING PATHW. c2.REACTOME HOST INTERACTIONS OF HIV FACTOR c2.WP CELLULAR PROTEOSTAS c2.REACTOME TRAFFICKING OF GLUR2 CONTAINING AMPA RECEPTOF c2.REACTOME ERYTHROPOIETIN ACTIVATES R./ c2.BIOCARTA GSK3 PATHW. c2.REACTOME MTORC1 MEDIATED SIGNALLIN c2.REACTOME IRON UPTAKE AND TRANSPOF c2.FARMER BREAST CANCER CLUSTER c2.MODY HIPPOCAMPUS POSTNAT. c2.BIOCARTA TFF PATHW, c2.REACTOME DOWNREGULATION OF ERBB2 ERBB3 SIGNALIN c2.CORONEL RFX7 DIRECT TARGETS U c2.REACTOME SIGNALING BY FLT3 FUSION PROTEIN c2.REACTOME SHC RELATED EVENTS TRIGGERED BY IGF- c2.BIOCARTA TPO PATHW, c2.FLECHNER PBL KIDNEY TRANSPLANT REJECTED VS OK U c2.PID LIS1 PATHW, c2.MYLLYKANGAS AMPLIFICATION HOT SPOT	AY RS RS AS AY NG RT A1 A1 A1 A1 A1 A1 A2 A1 A1 A2 A1 A2 A3 A4				
C2.MYLLYKANGAS AMPLIFICATION HOT SPOT C2.KEGG MEDICUS REFERENCE MICROTUBULE NUCLEATIO C2.PID PI3KCI AKT PATHW, C2.FLECHNER PBL KIDNEY TRANSPLANT OK VS DONOR I C2.BIOCARTA NGF PATHW, C2.SHEN SMARCA2 TARGETS I C2.BIOCARTA SPRY PATHW, C2.BIOCARTA SPRY PATHW, C2.PID RAC1 PATHW, C2.BIOCARTA P35ALZHEIMERS PATHW, C2.REACTOME NEPHRIN FAMILY INTERACTION C2.MYLLYKANGAS AMPLIFICATION HOT SPOT C2.REACTOME ACTIVATED NTRK2 SIGNALS THROUGH PI C2.REACTOME ACTIVATED NTRK2 SIGNALS THROUGH PI C2.REACTOME CREB1 PHOSPHORYLATION THROUGH THE ACTIVATION OF ADENYLATE CYCLAS C2.REACTOME FCGAMMA RECEPTOR FCGR DEPENDENT PHAGOCYTOS C2.REACTOME IRAK2 MEDIATED ACTIVATION OF TAK1 COMPLE C2.WP MICROTUBULE CYTOSKELETON REGULATIO C2.REACTOME TRANS GOLGI NETWORK VESICLE BUDDIN C2.JIANG MELANOMA TRM6 CI	DN AY				
c2.KEGG MEDICUS VARIANT MUTATION ACTIVATED USP8 TO EGFR ERK ACTH SIGNALING PATHW. c2.REACTOME REGULATION OF MECP2 EXPRESSION AND ACTIVIT c2.REACTOME FC EPSILON RECEPTOR FCER ISIGNALING c2.REACTOME DCC MEDIATED ATTRACTIVE SIGNALING c2.REACTOME DCC MEDIATED ATTRACTIVE SIGNALING c2.REACTOME INSERTION OF TAIL ANCHORED PROTEINS INTO THE ENDOPLASMIC RETICULUM MEMBRAN c2.WP TRANSCRIPTION FACTORS REGULATE MIRNAS RELATED TO CARDIAC HYPERTROPH c2.REACTOME SIGNALING BY MODERATE KINASE ACTIVITY BRAF MUTAN c2.PID NFAT 3PATHW. c2.WP FOLLICLE STIMULATING HORMONE FSH SIGNALIN c2.ABE INNER EX c2.BIOCARTA COKS PATHW. c2.WP RALA DOWNSTREAM REGULATED GENE c2.DAIRKEE CANCER PRONE RESPONSE B c2.KEGG MEDICUS REFERENCE LPA GNA12 13 RHOA SIGNALING PATHW. c2.REACTOME APC C MEDIATED DEGRADATION OF CELL CYCLE PROTEIN c2.REACTOME APC C MEDIATED DEGRADATION OF CELL CYCLE PROTEIN c2.REACTOME SEMA3A PAK DEPENDENT AXON REPULSIC c2.BANG VERTETPORFIN ENDOMETRIAL CANCER CELLS I c2.PARK HSC AND MULTIPOTENT PROGENITOR	TY VG VG VE VE VS				
c2.VISALA RESPONSE TO HEAT SHOCK AND AGING I c2.GERHOLD ADIPOGENESIS E c2.HOLLEMAN PREDNISOLONE RESISTANCE ALL I c2.REACTOME REGULATION OF ENDOGENOUS RETROELEMEN c2.LOPEZ TRANSLATION VIA FN1 SIGNALIN c2.CHIBA RESPONSE TO TSA E c2.REACTOME TRANSCRIPTIONAL ACTIVITY OF SMAD2 SMAD4 HETEROTRIME c2.HOSHIDA LIVER CANCER SUBCLASS: c2.PID RET PATHW, c2.PID EPHA2 FWD PATHW, c2.MILI PSEUDOPODIA CHEMOTAXIS U c2.BIOCARTA GCR PATHW. c2.REACTOME EGFR TRANSACTIVATION BY GASTR c2.KEGG MEDICUS VARIANT MUTATION ACTIVATED PI3K TO PI3K SIGNALING PATHW. c2.REACTOME LERMATAN SULFATE BIOSYNTHES c2.TERAO AOX4 TARGETS HG L c2.BERENJENO TRANSFORMED BY RHOA REVERSIBLY L	UP UP UP UP UP US SIG ON ER SIG AY				
C2.REACTOME WNT5A DEPENDENT INTERNALIZATION OF FZD2 FZD5 AND ROI	R2 AY AY AY BIS				
C2.REACTOME COPI DEPENDENT GOLGI TO ER RETROGRADE TRAFF C2.MCCLUNG DELTA FOSB TARGETS 8V C2.REACTOME ANTIGEN PROCESSING CROSS PRESENTATIV C2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER C2.WONG PROTEASOME GENE MODUL C2.REACTOME DEFECTIVE B4GALT7 CAUSES EDS PROGEROID TY C2.CAFFAREL RESPONSE TO THC L C2.PID CDC42 PATHW. C2.KEGG MEDICUS PATHOGEN KSHV VGPCR TO GNB G ERK SIGNALING PATHW. C2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER C2.BIDCARTA PKC PATHW. C2.YAO TEMPORAL RESPONSE TO PROGESTERONE CLUSTER C2.BIOCARTA PKC PATHW. C2.WP MITOCHONDRIAL COMPLEX III ASSEMB C2.CAFFAREL RESPONSE TO THC 24HR 5 L C2.LINDGREN BLADDER CANCER HIGH RECURRENC C2.KEGG MEDICUS PATHOGEN YERSINIA YOPP J TO TLR2 4 MAPK SIGNALING PATHW.	FIC VK ON ON ON ON ON ON AY AY AY AY AY AY AY AY ON				
C2.HEDENFALK BREAST CANCER BRACX E C2.HOUSTIS RC C2.STEARMAN LUNG CANCER EARLY VS LATE L C2.SILIGAN TARGETS OF EWS FLI1 FUSION L C2.REACTOME CITRIC ACID CYCLE TCA CYC! C2.REACTOME SIGNALING BY MI C2.PID NECTIN PATHW. C2.REACTOME IRS ACTIVATIC C2.BURTON ADIPOGENESIS C2.KEGG MEDICUS REFERENCE EGF EGFR PLCG ERK SIGNALING PATHW. C2.WP GLUCOSE METABOLISM IN TRIPLENEGATIVE BREAST CANCER CELI C2.WP EXERCISEINDUCED CIRCADIAN REGULATIC C2.REACTOME AKT PHOSPHORYLATES TARGETS IN THE CYTOSC C2.KEGG MEDICUS REFERENCE N GLYCAN PRECURSOR BIOSYNTHESIS ALG6 TO OS C2.KEGG MEDICUS REFERENCE N GLYCAN PRECURSOR BIOSYNTHESIS ALG6 TO OS C2.KEGG MEDICUS REFERENCE CXCR GNB G ERK SIGNALING PATHW. C2.WP METABOLIC REPROGRAMMING IN COLON CANCE C2.WP IL9 SIGNALIN C2.SHIPP DLBCL VS FOLLICULAR LYMPHOMA L C2.YIH RESPONSE TO ARSENITE (C2.YIH RESPONSE TO ARSENITE (C2.YIH RESPONSE TO ARSENITE (C2.YIH RESPONSE TO ARSENITE (C3.YIH RESPONSE	DN DS UP				
c2.YIH RESPONSE TO ARSENITE (c2.KEGG MEDICUS REFERENCE GLYCOLYS c2.MCBRYAN PUBERTAL BREAST 6 7WK U c2.REACTOME NEGATIVE REGULATION OF MET ACTIVI c2.KEGG MEDICUS REFERENCE DYNEIN RECRUITMENT TO THE KINETOCHOF c2.WIKMAN ASBESTOS LUNG CANCER U c2.PID WNT CANONICAL PATHW. c2.ISHIDA TARGETS OF SYT SSX FUSION c2.REACTOME REGULATION OF SIGNALING BY CI c2.HILLION HMGA1 TARGE c2.PID P53 REGULATION PATHW. c2.REACTOME CLECTA DECTIN 1 SIGNALIN c2.WANG RECURRENT LIVER CANCER U c2.BIOCARTA EIF2 PATHW. c2.KEGG MEDICUS REFERENCE AUTOPHAGOSOME AND LYSOSOME FUSION TRANS SNAF c2.BIOCARTA CCR5 PATHW. c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO TNF JNK SIGNALING PATHW. c2.KEGG MEDICUS VARIANT MUTATION CAUSED ABERRANT HTT TO TNF JNK SIGNALING PATHW. c2.SESTO RESPONSE TO UV (c2.SESTO RESPONSE TO	C2 SIS UP TY RE UP AY AY NS BL TS AY NG UP AY AY AY AY AC				
c2.SESTO RESPONSE TO UV (c2.SIG CHEMOTAX c2.KEGG MEDICUS REFERENCE FE3 FERRITIN TRANSPOI c2.REN ALVEOLAR RHABDOMYOSARCOMA E c2.REACTOME SIGNALING BY CYTOSOLIC FGFR1 FUSION MUTAN c2.MYLLYKANGAS AMPLIFICATION HOT SPOT c2.REACTOME ACTIVATED NTRK3 SIGNALS THROUGH RA c2.SA G1 AND S PHASE c2.SESTO RESPONSE TO UV (c2.FARDIN HYPOXIA c2.KEGG MEDICUS REFERENCE EARLY ENDOSOMAL FUSIC c2.REACTOME CELLULAR RESPONSES TO STIML c2.KEGG MEDICUS REFERENCE EGF RAS JNK SIGNALING PATHWA c2.PID HEDGEHOG GLI PATHWA c2.REACTOME TRANSPORT TO THE GOLGI AND SUBSEQUENT MODIFICATIC c2.REACTOME BUDDING AND MATURATION OF HIV VIRIO c2.XU RESPONSE TO TRETINIOIN AND NSC682994 E c2.BIOCARTA CBL PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA c2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWA	C8 KIS RT DN TS 22 AS ES C0 A 9 DN TE JLI JLI JLI AY AY ON DN DN DN DN DN AY AY AY				
C2.KEGG MEDICUS REFERENCE PDGF PDGFR PLCG CAMK SIGNALING PATHWAY C2.BURTON ADIPOGENESIS C2.WP HYPOTHESIZED PATHWAYS IN PATHOGENESIS OF CARDIOVASCULAR DISEAS C2.REACTOME CD209 DC SIGN SIGNALIN C2.REACTOME RNA POLYMERASE II TRANSCRIPTION TERMINATIC C2.REACTOME SWITCHING OF ORIGINS TO A POST REPLICATIVE STA' C2.WP LNCRNAMEDIATED MECHANISMS OF THERAPEUTIC RESISTANC C2.REACTOME TGFBR3 PTM REGULATIC C2.WP EXRNA MECHANISM OF ACTION AND BIOGENES C2.KYNG RESPONSE TO H202 VIA ERCC6 I C2.HOLLEMAN ASPARAGINASE RESISTANCE B ALL I C2.REACTOME RAP1 SIGNALIN C2.REACTOME HEDGEHOG ON STA' C2.PID SYNDECAN 2 PATHW, C2.KEGG MEDICUS VARIANT AMPLIFIED PDGFR TO PI3K SIGNALING PATHW, C2.WP COMMON PATHWAYS UNDERLYING DRUG ADDICTIC C2.REACTOME AUTOPHAC C2.ITO PTTG1 TARGETS L C2.HWANG PROSTATE CANNER MARKEF	AY 12 SE NG ON TE CE ON				
c2.HWANG PROSTATE CANCER MARKEF c2.WP PGK1 PKM2 KHKCKHKA ACTING AS PROTEIN KINASE c2.REACTOME MAPZK AND MAPK ACTIVATIC c2.REACTOME MAPZK AND MAPK ACTIVATIC c2.REACTOME GLYCINE DEGRADATIC c2.REACTOME CELLULAR RESPONSE TO MITOCHONDRIAL STREE c2.YANAGIHARA ESX1 TARGE c2.BANDRES RESPONSE TO CARMUSTIN MGMT 24HR L c2.PID CXCR3 PATHW. c2.REACTOME GLYCING GRACH COLOR c2.REACTOME GROUNG GRACH COLOR c2.REACTOME RHOU GTPASE CYC c2.DI MARTINO MATRISOME HIGHLY PROLIFERATIVE HNSCC TUMOR CELL DERIVE c2.WP MITOCHONDRIAL COMPLEX I ASSEMBLY MODEL OXPHOS SYSTE c2.REACTOME SCAVENGING BY CLASS F RECEPTOR c2.REACTOME SCAVENGING BY CLASS F RECEPTOR c2.REACTOME P38MAPK EVENT c2.REACTOME RMTS METHYLATE HISTONE ARGINING c2.REACTOME RMTS METHYLATE HISTONE ARGINING c2.KEGG MEDICUS PATHOGEN HCMV GH TO ITGA B RHOA SIGNALING PATHW. c2.GENTILE UV RESPONSE CLUSTER I c2.OUYANG PROSTATE CANCER PROGRESSION I c2.MARIADASON RESPONSE TO CURCUMIN SULINDAC	RS ES ES DON DON DON SS TS UP AY LE ED EM NG RS TS AY AY LE ES AY				
c2.MARIADASON RESPONSE TO CURCUMIN SULINDAC c2.REACTOME CELLULAR RESPONSE TO CHEMICAL STRES c2.REACTOME REGULATION OF TP53 ACTIVITY THROUGH ACETYLATIC c2.REACTOME HDACS DEACETYLATE HISTONE c2.CREIGHTON AKT1 SIGNALING VIA MTOR IE c2.PID TRKR PATHW, c2.STARK PREFRONTAL CORTEX 22Q11 DELETION IE c2.KEGG MEDICUS REFERENCE E2 ER RAS ERK SIGNALING PATHW, c2.KEGG MEDICUS REFERENCE E2 ER RAS ERK SIGNALING PATHW, c2.KEGG MEDICUS REFERENCE E2 ER RAS ERK SIGNALING PATHW, c2.REACTOME REGULATION OF ENDOGENOUS RETROELEMENTS BY PIWI INTERACTING RNAS PIRW, c2.REACTOME REGULATION OF RUNX1 EXPRESSION AND ACTIVI c2.REACTOME GOLGI CISTERNAE PERICENTRIOLAR STACK REORGANIZATIC c2.ZAMORA NOS2 TARGETS IC c2.BIOCARTA EPO PATHW, c2.REACTOME SIGNALING BY CSF1 M CSF IN MYELOID CELL c2.CHANG POUSF1 TARGETS IC c2.CHANG POUS	C 7 SS DN				
	SP UP	0.0 0.2 0.4 Z_SCO	0.0 0.2 0.4 ore	0.0 0.2 0.4	